Centessa Pharmaceuticals (CNTA) Other Non Operating Income (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Other Non Operating Income data on file, last reported at -$1.0 million in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$1.0 million, down 199.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 334.13% YoY), and the FY2024 annual result was -$1.7 million, changed N/A from the prior year.
• Other Non Operating Income rose to -$1.0 million in Q1 2026 per CNTA's latest filing, from -$2.8 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $5.4 million in Q2 2022 and troughed at -$4.0 million in Q4 2024.
• A 5-year average of -$21764.7 and a median of -$1.0 million in 2026 frame the typical range for Other Non Operating Income.
• On a YoY basis, Other Non Operating Income climbed as much as 6600.0% in 2023 and fell as far as 786.73% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at -$70000.0 in 2022, then soared by 6600.0% to $4.6 million in 2023, then tumbled by 187.21% to -$4.0 million in 2024, then advanced by 29.23% to -$2.8 million in 2025, then jumped by 63.5% to -$1.0 million in 2026.
• Business Quant data shows CNTA's Other Non Operating Income at -$1.0 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.8 million in Q3 2025.